BALCAO · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
Aspira Women’s Health Inc. AWHL
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.2M
▲ 0.4% vs FY2024
EPS · FY25
$-0.37
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-138.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.2M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 139 cents on every revenue dollar this year.
Per share
USD -0.37
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-85.9%
Net margin-138.7%
Return on assets-233.5%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+14.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+4.0%
+14.7%
+15.5%
+14.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+100.8%
Change, 10 years—
The share count grew 101% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.5M
total assets, end of FY2025
Total assetsUSD 5.5M
EquityUSD -6.9M
CashUSD 1.8M
Gross debtUSD 1.3M
Net debtUSD -478,000.00
Current ratio1.17×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.37
−0.93
−1.81
−3.85
−4.27
−0.18
−0.18
−0.16
−0.20
−0.29
−0.41
−0.53
−0.42
−0.48
−1.25
−1.83
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−723.5
−160.9
−158.7
−194.0
−191.8
−215.4
−292.8
−140.5
−103.9
−83.5
−56.1
−95.1
−237.6
−412.3
Shares out B
0.04
0.02
0.01
0.01
0.01
0.10
0.10
0.08
0.06
0.05
0.05
0.04
0.04
0.02
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
63 of 63
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed